Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Charles Gerrits"'
Autor:
Erica Birk, Intekhab Hossain, Joel Iff, Edward Tuttle, Gautam Sajeev, Charles Gerrits, James Signorovitch, Courtney Ng, Zhiwen Yao, Nathalie Goemans, André Müller-York
Publikováno v:
Neuropediatrics.
Autor:
Keziah Cook, Rebecca J. Brown, Charles Gerrits, Omer A. Ali, Kristina S. Shampanier, Edward Tuttle
Publikováno v:
Diabetes. 67
Effects of LRT on metabolic disease in GL and PL have been studied; however, little is known about consequences of GL and PL, or the effect of LRT, on quality of life (QoL). To characterize health utility consequences of GL and PL attributes on patie
Publikováno v:
The American journal of managed care. 23(2)
To assess the impact of hypoglycemia and potential underlying factors of economic burden in patients with type 2 diabetes (T2D) who are initiating basal insulin therapy.This retrospective cohort study combined commercial insurance and Medicare Advant
Autor:
Karol LaCroix, Ken Hornbuckle, Joseph M. Tonning, Chuen Yee, Susan Sacks, Robert Ball, Mike Johnston, A. Lawrence Gould, Harry A. Seifert, Rita Ouellet-Hellstrom, June S. Almenoff, Charles Gerrits, Manfred Hauben, Louisa Walsh, Nancy A. Yuen, Michael D. Blum, Vaishali Patadia, Ana Szarfman
Publikováno v:
Drug Safety. 28:981-1007
In the last 5 years, regulatory agencies and drug monitoring centres have been developing computerised data-mining methods to better identify reporting relationships in spontaneous reporting databases that could signal possible adverse drug reactions
Autor:
Christian Frois, Aleksandra Vlajnic, Quanwu Zhang, Daisy Zhuo, Hsing-wen Chung, Hongwei Wang, Walter Lehmacher, Charles Gerrits, Nick Freemantle, Eric Q. Wu, Engels Chou
Publikováno v:
BMJ Open
Objective To compare the efficacy and safety of a concentrated formulation of insulin glargine (Gla-300) with other basal insulin therapies in patients with type 2 diabetes mellitus (T2DM). Design This was a network meta-analysis (NMA) of randomised
Autor:
Shiraz R. Gupta, Andrew P. Yu, Yanjun Bao, James Signorovitch, Parvez Mulani, Eric Q. Wu, Charles Gerrits, Evan Kantor
Publikováno v:
PharmacoEconomics. 28(10)
The absence of head-to-head trials is a common challenge in comparative effectiveness research and health technology assessment. Indirect cross-trial treatment comparisons are possible, but can be biased by cross-trial differences in patient characte